Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.
作者信息
Kater Arnon P, Tonino Sanne H, Spiering Marjolein, Chamuleau Martine E D, Liu Roberto, Adewoye Adeboye Henry, Gao Jie, Dreiling Lyndah, Xin Yan, Doorduijn Jeanette K, Kersten Marie José
机构信息
Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
Lymphoma and Myeloma Center (LYMMCARE), Academic Medical Center, Amsterdam, The Netherlands.
出版信息
Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x.
Abstract
摘要
Zotero 插件